The Opioid Crisis: Context Behind the Numbers The U.S. opioid overdose death rate reached 107,622 in 2023—a 38% increase since 2019. This epidemic traces directly to pharmaceutical marketing practices of the 1990s, when Purdue Pharma aggressively promoted OxyContin to physicians with claims of low addiction risk later proven false; the company paid $600 million in settlements but faced minimal criminal accountability. Synthetic fentanyl, 50-100 times more potent than morphine and undetectable to users mixing street drugs, became the primary driver of overdose deaths by 2015, replacing prescription pills as the dominant threat. Understanding this timeline matters because policy responses continue focusing on individual treatment rather than the structural failures—regulatory capture, pharmaceutical liability shields, and inadequate enforcement—that enabled mass distribution of addictive drugs to begin with.